Showing results (321-330 of 395) with videos related to

Sort By:
Pageof 40
Journal of Acquired Immune Deficiency Syndromes (1999)|August 19, 2024
The Diagnostic Performance of the Visitect Advanced Disease Point-Of-Care CD4 Platform: A Pragmatic, Mixed-Methods, Multisite Validation, Costing, and Qualitative AnalysisElizabeth Nalintya, Preethiya Sekar, Olive L Namakula, et al.
Open Forum Infectious Diseases|May 5, 2020
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)Katelyn A Pastick, Elizabeth C Okafor, Fan Wang, et al.
Open Forum Infectious Diseases|February 12, 2020
Seizures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Predictors and OutcomesKatelyn A Pastick, Ananta S Bangdiwala, Mahsa Abassi, et al.
Medrxiv : the Preprint Server for Health Sciences|January 3, 2024
Utility of Cerebrospinal Fluid Protein Levels as a Potential Predictive Biomarker of Disease Severity in HIV-Associated Cryptococcal MeningitisJohn Kasibante, Eesha Irfanullah, Abduljewad Wele, et al.
Tropical Medicine & International Health : TM & IH|October 5, 2016
Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, BrazilJosé E Vidal, Carolina Toniolo, Adriana Paulino, et al.
Plos One|January 6, 2018
Evaluation of a point-of-care immunoassay test kit 'StrongStep' for cryptococcal antigen detectionEdward Mpoza, Liliane Mukaremera, Didas Atwebembere Kundura, et al.
Medical Mycology|October 17, 2024
Clinical importance of cerebrospinal fluid protein levels in HIV-associated cryptococcal meningitis: Insights from a prospective cohort study in UgandaJohn Kasibante, Eesha Irfanullah, Abduljewad Wele, et al.
Brain, Behavior, and Immunity|December 28, 2020
Sex-specific associations between cerebrospinal fluid inflammatory marker levels and cognitive function in antiretroviral treated people living with HIV in rural UgandaAlyssa C Vecchio, Dionna W Williams, Yanxun Xu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2021
High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled TrialFiona V Cresswell, David B Meya, Enock Kagimu, et al.
Open Forum Infectious Diseases|July 1, 2024
A Comparison of Recruitment Methods for a Remote, Nationwide Clinical Trial for COVID-19 TreatmentKatrina M Hartman, Barkha Patel, Via Rao, et al.
Pageof 40